Lower levels of LAMP-2A were found in early-stage PD patient brains compared to healthy controls, along with an accumulation of α-syn and other CMA substrates such as myocyte-specific enhancer factor 2D (MEF2D) [128,140]. This evidence concerns the gene MEF2D and Parkinson disease.